Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation
- Author:
Eun Kyung KIM
1
;
Seung Hoon LEE
;
Seon Young LEE
;
Jae kyung KIM
;
Joo Yeon JHUN
;
Hyun Sik NA
;
Se Young KIM
;
Jong Young CHOI
;
Chul Woo YANG
;
Sung Hwan PARK
;
Mi La CHO
Author Information
- Publication Type:Original Article
- MeSH: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Arthritis; Arthritis, Experimental; Arthritis, Rheumatoid; Autoimmune Diseases; Diet, High-Fat; In Vitro Techniques; Inflammation; Joints; Metabolome; Metformin; Mice; Mice, Obese; Models, Theoretical; Obesity
- From:Experimental & Molecular Medicine 2018;50(1):e432-
- CountryRepublic of Korea
- Language:English
- Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease involving excessive inflammation. Recently, RA associated with a metabolic disorder was revealed to be non-responsive to RA medications. Metformin has been reported to have a therapeutic effect on RA and obesity. The aim of this investigation was to study the therapeutic effect and the underlying mechanism of metformin's action in an experimental model of collagen-induced arthritis (CIA) associated with obesity. Metformin was administered daily for 13 weeks to mice with CIA that had been fed a high-fat diet. Metformin ameliorated the development of CIA in obese mice by reducing autoantibody expression and joint inflammation. Furthermore, metformin decreased the expression levels of pSTAT3 and pmTOR and had a small normalizing effect on the metabolic profile of obese CIA mice. In addition, metformin increased the production of pAMPK and FGF21. Metformin also induced the differentiation of brown adipose tissue (BAT), which led to a reciprocal balance between T helper (Th) 17 and regulatory T (Treg) cells in vitro and in vivo. These results suggest that metformin can dampen the development of CIA in obese mice and reduce metabolic dysfunction by inducing BAT differentiation. Thus, metformin could be a therapeutic candidate for non-responsive RA.
